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One of the critical steps that governs the inhibitory effect of antisense RNA on target gene expression is the association of
the antisense RNA with the target RNA molecules. However, until now, no systematic method has been available to select
the suitable parts of a gene as antisense targets. In this study, we utilised U1 small nuclear RNA (snRNA) that binds
physiologically to the 5' splice site (5'ss) of pre-mRNA, to develop a novel vector system that permits imposed binding of
antisense RNA to its target. The 5' free end of U1snRNA was replaced with the antisense sequence against the K-ras gene to
generate a hyperstable U1snRNA, whose binding stability to 5'ss of the K-ras transcript is ten-fold higher than that of wild-
type U1snRNA. The efﬁcacy of such hyperstable U1snRNA was examined by transducing the expression plasmids into human
pancreatic cancer cell lines. This revealed that two of the hyperstable U1snRNAs induced cell death after gene transduction,
and signiﬁcantly reduced the number of G418-resistant colonies to less than 10% of the controls. Furthermore, hyperstable
U1snRNA suppressed intraperitoneal dissemination of pancreatic cancer cells in vivo. Hyperstable U1snRNA might be a novel
approach to express effective antisense RNA in target cells.
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Suppression of undesirable gene expression is one important object
of gene therapy. It is of particular importance in the development
of gene therapy against cancer, in which activated oncogenes play a
critical role in neoplastic propagation. A large body of knowledge
has accumulated which demonstrates that both antisense oligonu-
cleotides, as well as antisense expression vectors against an
activated oncogene, can suppress the transformed phenotypes and
tumorigenicity of cancer cell lines (Carter and Lemoine, 1993; Aoki
et al, 1995, 1997; Gewirtz et al, 1998; Kita et al, 1999). Since
systemic administration of an antisense oligonucleotide has adverse
effects due to its non-speciﬁc toxicity (Agrawal and Zhao, 1998a,b),
it is an urgent task to develop a more efﬁcient antisense vector
system and to improve the technique of introducing a foreign gene
into target cells.
For the expression of antisense RNA in vivo, various vector
systems have been developed using RNA polymerase II or III
dependent promoters (Strauss, 1997). Although the RNA polymer-
ase II (pol II)-dependent promoter has been used widely, it has
disadvantages. For example, the transcribed antisense product is
processed as mRNA, polyadenylated, and exported from the
nucleus to the cytoplasm where it is eventually degraded. Such a
process could be partly responsible for the fact that a short anti-
sense RNA transcribed by pol II was relatively unstable (He and
Huang, 1997). The pol III-dependent promoters of small RNA
species, such as tRNA and U6snRNA, have been an attractive alter-
native (Konforti et al, 1993; Noonberg et al, 1994). However, the
use of these pol III-dependent promoters limits the design of anti-
sense RNA, because pol III transcription was found to be impeded
by several sequences, which prematurely terminated the transcrip-
tion (He et al, 1997; Das et al, 1988).
Despite many efforts, a general algorithm for choosing the best
antisense targets has not yet been established. This is partly because
there is no method to predict the accessibility of antisense RNA to
the target site in the secondary structure of an RNA molecule.
Furthermore, mRNA forms a complex with proteins in both
nucleus and cytosol (Larson and Sells, 1987; Dreyfuss et al,
1993), which makes the selection of an effective antisense sequence
largely a matter of trial and error (Birikh et al, 1997; Strauss, 1997;
Gewirtz et al, 1998).
Among the small nuclear RNAs (snRNA), U1snRNA is the most
abundant snRNA that is transcribed by pol II. It participates in the
recognition of 5' splice site (5'ss) during pre-mRNA splicing by
binding to the 5'ss consensus sequence. This interaction is
mediated by the 5'-free end of U1snRNA, which has a 9 base-long
complementary sequence to the consensus (Mount et al, 1983;
Sharp, 1994; Black, 1995). It has been well documented that the
introduction of mutations in this 5'-free end can alter the binding
speciﬁcity of U1snRNA to the 5'ss (Zhuang and Weiner, 1986;
Hitomi et al, 1998).
These properties of U1snRNA, especially the physiological bind-
ing to pre-mRNA, could render it beneﬁcial as a carrier of an
antisense sequence against a target transcript, if the sequence at
the 5'-free end could be replaced with an antisense sequence.
The remaining U1snRNA sequence might stabilise the antisense
RNA as a ribonucleoprotein complex, guide it to the pre-mRNA
of the target gene, and facilitate association of the antisense RNA
to the target site. In addition to conventional antisense effects, if
an antisense sequence was long enough to far exceed the binding
stability between wild-type U1snRNA and pre-mRNA, it is possible
that such hyperstable U1snRNA might disturb the splicing of the
target gene transcripts.
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www.bjcancer.comIn this study, we constructed an antisense expression plasmid
based on the U1snRNA gene, and designed hyperstable U1snRNA
against the human K-ras transcript. The efﬁcacy of the hyperstable
U1snRNA was examined using three pancreatic cancer cell lines,
which have been employed previously to demonstrate the inhibi-
tory effects of K-ras antisense oligonucleotides (Kita et al, 1999)
or expression vectors (Aoki et al, 1995, 1997).
MATERIALS AND METHODS
Plasmids
The U1snRNA expression vector has been described elsewhere
(Hitomi et al, 1998). The NdeI site was created within the region
of the 5'-free end of U1snRNA, using mutated oligomers GAT
CTC ATA TGG CAG GGG AGA TAC and TCC CCT GCC ATA
TGA GAT CTT GG, generating pEUK/nU1. Antisense and sense
oligomers of ﬁve target sequences in the K-ras gene (see Figure
1C) were annealed and ligated with pEUK/nU1 digested with NdeI.
The orientation of the insert was conﬁrmed by sequencing, and
plasmids were designated, according to the orientation of the
insert, as r1A or r1S for antisense or sense against the r1 target site,
respectively. The neomycin-resistant gene was subcloned between
XhoI and HindIII sites in pEUK/nU1, where it was under the
control of SV40 late promoter.
Cell culture
Pancreatic carcinoma cell lines, PANC-1, AsPC-1 and BxPC-3 were
cultured in DMEM with 10% foetal calf serum (FCS), RPMI-1640
with 20% FCS, and RPMI-1640 with 10% FCS under 5% CO2 at
378C, respectively. COS-1 was cultured in DMEM with 10%
FCS. PANC-1 and AsPC-1 have a point mutation in K-ras codon
12, while BxPC-3 has the wild-type K-ras gene (Berrozpe et al,
1994)
Transfection
COS-1 was electroporated with 10 mg of the plasmid at 300 V and
960 mF. Transfection for pancreatic cancer cell lines was performed
with transfectum or lipofectamine reagents (GibcoBRL, Rockville,
MD, USA) as described by Aoki et al (1995). Brieﬂy, the day before
transfection, 1610
5 cells were plated in a 6 cm dish. DNA and the
transfection reagent in serum-free Opti-MEM (GibcoBRL) were
overlaid onto the cells. The transfection was halted at 6 h for
PANC-1 and AsPC-1, and at 3.5 h for BxPC-3. Transfection efﬁ-
ciency was always monitored by introducing pEGFP-C1 in
parallel and examining the green ﬂuorescence microscopically. To
establish permanent transfectants, selection with G418 was started
48 h after transfection. After selection for 2 weeks, the number
of colonies was counted, and each colony was cloned in the case
of r1A and r3A transfectants. For the other transfectants, G418-
resistant colonies were pooled and maintained as a mixed popula-
tion of G418-resistant cells.
Northern blot analysis
Total RNA was extracted by acid guanidinium thiocyanate-phenol-
chloroform extraction (Chomczynski and Sacchi, 1987). Three mg
of total RNA was electrophoresed on a denaturing 5% polyacryla-
mide gel containing 7 M urea, and stained with 5 mgm l
71 of
ethidium bromide. The fractionated RNA was electroblotted onto
a nylon membrane, hybridised with appropriate 20 base-long oligo-
nucleotides to detect an antisense or sense K-ras sequence in
hyperstable U1snRNA, and visualised by exposure against an
imaging plate (BAS-2000 system, Fuji, Japan). The membrane
was also hybridised with an U1snRNA-speciﬁc oligomer CCA
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
187 b
164 b —
187 b —
187 b
164 b —
187 b —
r1 r2 r3 r4 r5
 A   S  A   S  A   S      S  A   S COS-1
— a U1
— wt U1
— U2
— s U1
— wt U1
— U2
—
—
r1 r2 r3 r4 r5
 A  S  A  S  A    S A   S  A   S COS-1
Promoter
U1snRNA
100 bp
Wild type
nU1
aagatctc
aagatct
hyperstable U1snRNA
ATACTTACCTGGCAGGG
GCAGGGGATATA cATATG
3mGpppAU NNNNNNNNNNNNN
NNNNNNNNNNNNN
AU
Target sequence
50 bp
r1
r2
r3
r4
r5
1 2 3
r1-20 r2-20 r4-20
3' 5'
3'
3' 5'
D
A
B
C
5'
 A   
Figure 1 Construction of the hyperstable U1snRNA vector. (A) In the
human U1snRNA gene (Hitomi et al, 1998), six- bases were deleted to
generate a NdeI site in the region of the 5'-free end of U1snRNA. The re-
sulting sequence in this region (nU1) is shown with respect to the wild-type
sequence. The newly created NdeI site is boxed and the arrowhead indi-
cates the cleavage site. (B) Insertion of the antisense sequence in the
U1snRNA gene generates hyperstable U1snRNA, which binds to the target
site via the inserted sequence in the 5'-free end of U1snRNA. The second-
ary structure of U1snRNA is shown as a line drawing. (C) The target sites
against the human K-ras transcript are indicated as r1, r2, r3, r4 and r5,
aligned to the corresponding K-ras gene structure. The K-ras exons 1, 2,
and 3 are indicated by the numbered boxes. The sites of the 20 base-long
oligonucleotides used for northern analysis are also indicated as r1-20 for
the detection of r1, r2-20 for r2, r4-20 for r3, r4, and r5. The relative
lengths of the target sites, exons, and oligonucleotides are ﬁtted to the scale
shown above, whereas the intron sequences are shortened. (D) Transient
expression of hyperstable U1snRNA in COS-1. The expression plasmid of
hyperstable U1snRNA was transfected into COS-1. Three mg of total RNA
was separated on a 5% polyacrylamide/7 M urea gel, electroblotted and hy-
bridised with radiolabelled sense (upper panels) or antisense (lower panels)
K-ras oligonucleotides corresponding to the target sites, r1 to r5. The posi-
tion of antisense hyperstable U1snRNA (aU1), sense hyperstable
U1snRNA (sU1), and wild-type U1snRNA (wtU1, 164 bases) is indicated.
The integrity and load of RNA was examined by hybridizing the same
membrane with U2B, an U2snRNA-speciﬁc oligonucleotide.
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oligomer AAC AGA TAC TAC ACT TG.
Immunoblotting
Cells were lysed directly in buffer containing 100 mM Tris-HCl
(pH 6.8), 2.5% sodium dodecylsulfate, 20% glycerol, 2 mM phenyl-
methylsulphonyl ﬂuoride, 2 mM b-mercaptoethanol, and 0.005%
bromophenol blue. Total cell lysates (100 mg protein) were heated
at 1008C, separated by 12% denaturing polyacrylamide gel, and
electroblotted onto polyvinylidene diﬂuoride membrane (Millipore,
Bedford, MA, USA). The K-ras protein was detected by a K-ras-
speciﬁc p21 monoclonal antibody (Oncogene Research Products,
Boston, MA, USA) by using enhanced chemiluminescence system
(Amersham Pharmacia Biotech, Upsala, Sweden).
In vivo tumorigenicity assay
The tumorigenicity of stable PANC-1 transfectants of the hyper-
stable U1snRNA plasmid was examined by injecting 3610
6 cells
subcutaneously into 6 week-old male BALB/c nu/nu mice. Tumour
formation was monitored for 3 months. The volume of each
tumour was approximated by the formula: tumour volu-
me=r
26l/2, where r and l are two orthogonal measurements of
tumour diameter (Gray et al, 1993).
Effects of hyperstable U1snRNA on the peritoneal
dissemination model
AsPC-1 of 5610
5 cells was injected intraperitoneally into three 6
week-old male BALB/c nu/nu mice in each experimental group
(Aoki et al, 1995). Three days after tumour cell injection,
100 mg of the hyperstable U1snRNA plasmid was mixed with lipo-
fectamine (GibcoBRL, USA) and injected intraperitoneally three
times at 12 h intervals. The mice were sacriﬁced 28 days after
the cell injection and examined for the development of peritoneal
dissemination.
RESULTS
Construction of the hyperstable U1snRNA plasmids
To develop the novel antisense expression vector based on the
U1snRNA gene, a cloning site was created in the U1snRNA gene,
which allowed the insertion of any desirable sequence into the
5'-free end of U1snRNA (Figure 1A,B). To determine the maxi-
mum length of a sequence that can be stably expressed in
conjunction with U1snRNA, double-stranded nucleotides of
various lengths ranging from 20 to 100 bases long were inserted
into the U1snRNA gene, and the generated plasmids were intro-
duced transiently into COS-1. Northern analysis showed that the
hyperstable U1snRNAs acquiring the 60 base-long insert were
expressed at comparable levels to those having only 20 to 40 base
inserts, whereas the expression levels of the 80 to 100 base inserts
seemed to depend on the sequence joined to U1snRNA (data not
shown).
Based on these ﬁndings, several 60 base-long sequences from the
human K-ras gene were selected to examine the efﬁcacy of the
hyperstable U1snRNA (Figure 1C). The sequence of r1 was
designed to cover the short exon 1 sequence including both 3'
and 5'ss regions. The r3, r4, and r5 sequences spanned the 5' splice
site of the second intron. Their sequences were each shifted 20
bases from one another, while the r2 sequence was in the middle
region of exon 2 (see Figure 1C). The binding stability of these
60 base-long RNAs ranges from 785.6 to 7115.8 kcal mol
71,
which is about 10 times higher than that of wild-type U1snRNA
(Freier et al, 1986; Hitomi et al, 1998).
These hyperstable U1snRNAs were transfected into COS-1 tran-
siently and the expression was examined by Northern hybridisation
with K-ras-speciﬁc oligomers. All types of hyperstable U1snRNA
were expressed at similar levels and showed identical lengths
(Figure 1D). The relative mobility of these bands, compared to
the wild-type U1snRNA and U2snRNA, was consistent with an
expected length of about 60 bases longer than the wild-type
U1snRNA. These bands could also be detected with an
U1snRNA-speciﬁc antisense oligomer, which indicated that these
bands actually consisted of the K-ras-speciﬁc sequence and
U1snRNA (data not shown).
Reduction of G418-resistant colony formation by r1A and
r3A hyperstable U1snRNAs
To investigate the effect of hyperstable U1snRNA on cell growth
of a pancreatic cancer cell line that expressed the activated K-
ras gene, these constructs were transfected into PANC-1. Two
days after transfection, we noticed that the cell density was
slightly lower in the dishes transfected with r1A and r3A
compared to the control dishes transfected with hyperstable
U1snRNAs having the sense orientation of the K-ras sequence
or wild-type U1snRNA (data not shown). The reduction in
the number of attached cells after r1A or r3A transfection could
have resulted from an interference with cell attachment,
suppression of proliferation, or induction of cell death. The ﬁrst
possibility was discarded in part by examining the degree of
trypan blue exclusion in the ﬂoating cells after transfection. It
showed that all cells were readily stained with the dye. Thus,
considering transfection efﬁciency of these cell lines, which is
at most 35%, almost all of the cells transfected with r1A or
r3A should slow or cease their proliferation immediately after
transfection.
To examine this possibility, the neomycin-resistant gene was
subcloned into the hyperstable U1snRNA constructs and selected
the G418-resistant transfectants of PANC-1, AsPC-1, and BxPC-
3. If r1A and r3A were able to retard cell proliferation, perma-
nent transfectants should form smaller colonies than control
transfectants. Surprisingly, after 2-weeks selection, the number
of G418-resistant colonies was signiﬁcantly decreased in r1A
and r3A transfectants, in both PANC-1 and AsPC-1 (Figure
2A,B). Furthermore, several colonies transfected with r1A and
r3A were signiﬁcantly smaller than others. Since such differences
were not observed with BxPC-3 transfectants (Figure 2C), it is
unlikely that co-expression of the hyperstable U1snRNA simply
interfered with the expression of the neomycin-resistant gene.
These observations were conﬁrmed by repeating the experiments;
they suggested that r1A and r3A interfered speciﬁcally with the
survival of pancreatic carcinoma cells that harbored the activated
K-ras gene.
Analysis of stable transfectants of r1A or r3A hyperstable
U1snRNA
The induction of cell death so soon after transfection made it
difﬁcult to analyse the underlying mechanism biochemically
using the transiently transfected cells. However, since the size
of several colonies selected with G418 was apparently smaller
in r1A and r3A than in the controls, we speculated that these
surviving cells expressed relatively low levels of U1snRNA,
which permitted colony formation. Thus, we characterised these
clones of PANC-1 cells transfected with r1A and r3A (see Table
1). Among these clones, two out of six r1A-transfected PANC-1
clones (Pr1A) and three out of ﬁve Pr3A clones were quite
heterogeneous in morphology, and grew three to four times
more slowly than other colonies (Table 1 and Figure 3). These
slow growing colonies contained signiﬁcant numbers of multi-
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with a dark pyknotic nucleus. Furthermore, cell culture of these
clones was always accompanied by a signiﬁcant number of
ﬂoating cells that could be stained readily with trypan blue,
even after replacing with fresh medium. These features were
not observed in PANC-1 colonies transfected with r1S, r3S,
wild-type U1snRNA, or the neomycin-resistant gene only. All
colonies grown in these control dishes were uniform in size
and morphology, which were indistinguishable from those of
the parent cell line. During subsequent cell culture for biochem-
ical analysis, Pr1A-6 and Pr3A-3 gradually lost their
morphological heterogeneity with their cells becoming more like
the parent PANC-1 cell, whereas cell clones Pr3A-4, Pr3A-5,
and Pr1A-4 retained their morphological heterogeneity (Table
1). As shown in Figure 4A, immunoblot analysis using the
minimum number of cells at early passage indicated that K-
ras p21 expression was lower in all Pr1A clones and in two
of the Pr3A clones (Pr3A-4 and Pr3A-5) than in the other
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Figure 2 Effect of hyperstable U1snRNA on cell growth and colony for-
mation of pancreatic cancer cell lines. Three pancreatic cancer cell lines,
PANC-1 (A), AsPC-1 (B), and BxPC-3 (C) were plated at 1610
5 cells
in each 6 cm dish and transfected with the hyperstable U1snRNA plasmids
having the neomycin-resistant gene (neo
r). The vehicle vector was also
transfected to establish control cells. The number of developed colonies
was counted after 2-weeks selection with G418.
Figure 3 Cell morphology of PANC-1 clones transfected with hyper-
stable U1snRNA. Parent PANC-1 (A) and transfectants, Pr1A-4 (B),
Pr1S (C), Pr3A-4 (D), Pr3A-5 (E), and Pr3S (F) were cultured to conﬂu-
ence and photographed at a magniﬁcation of 6200. The r1A and r3A
transfected clones are heterogeneous in their cell morphology and contain
many multinucleated giant cells.
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Figure 4 (A) Western blot analysis of p21 K-ras proteins. Total cell ly-
sates (100 mg), prepared from parent and stable transfectants at early pas-
sage, were subjected to 12% SDS–PAGE, transferred to a membrane, and
blotted with K-ras p21-speciﬁc monoclonal antibody. (B) Expression of hy-
perstable U1snRNA in PANC-1. The cells were transfected with the hyper-
stable U1snRNA plasmids and selected with G418. Total RNA (3 mg) was
separated on a 5% polyacrylamide/7 M urea gel, blotted on a membrane,
and hybridised with radiolabelled sense (upper panels) or antisense (lower
panels) K-ras oligonucleotides corresponding to the target sites r1 to r5
(see Figure 1B). The position of antisense hyperstable U1snRNA (aU1),
sense hyperstable U1snRNA (sU1), and wild-type U1snRNA (wtU1, 164
bases) is indicated. Hybridisation with U2B veriﬁed the integrity and load
of RNA.
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after multiple cell passages.
Suppression of tumorigenicity in the stable r1A or r3A
transfectants
Expression of hyperstable U1snRNA was examined by Northern
analysis. It revealed that the expression of hyperstable U1snRNA
was detected in half of these clones, including Pr1A-4, Pr3A-4,
and Pr3A-5 (Figure 4B). To investigate the signiﬁcance of hyper-
stable U1snRNA expression, we tested the tumorigenicity of these
clones. Three of the poor-growing and U1-positive clones (Pr1A-
4, Pr3A-4, and Pr3A-5) and one rapidly growing and U1-nega-
tive clone (Pr1A-2) were injected in nude mice subcutaneously,
in parallel with Pr1S, Pr3S, Pwt, and PANC-1. Two weeks after
tumour injection, small nodules were palpable and these gradu-
ally enlarged in the control groups. After 3 months, no
tumour formation was found in Pr1A-4, Pr3A-4 (Figure 5B,E),
and Pr3A-5 (data not shown), even though the tumours in the
control animals injected with parent cells (Pr1S or Pr3S) had
enlarged to more than 60 mm
3 (Figure 5A,D,F,G). In contrast,
Pr1A-2 formed tumours that were about one-third the volume
of the parent cell tumours (Figure 5C,G). Therefore, the expres-
sion of hyperstable U1snRNA appeared to suppress the
tumorigenicity of PANC-1.
Suppression of intraperitoneal dissemination of AsPC-1 by
r1A or r3A hyperstable U1snRNA
Finally, the therapeutic effect of r1A and r3A was examined using
the abdominal dissemination model of AsPC-1 (Aoki et al, 1995).
The results are summarised in Table 2. Two weeks after cell
implantation into the peritoneal cavity, parent AsPC-1 cells formed
multiple nodules on the surface of the liver and pancreas, and on
the mesentery. However, no tumour nodules were observed in
animals that were administered with r1A or r3A, except for a single
nodule found on the mesentery of one animal treated with r1A.
These ﬁndings are in marked contrast to animals injected with
r1S or r3S, which showed no essential difference from controls
administered with the liposome only or with TE (Table 2). Macro-
scopically, there was no sign of a general or a local adverse effect of
the hyperstable U1snRNA. Therefore, these results indicate that the
hyperstable U1snRNA suppressed the peritoneal dissemination of
implanted AsPC-1.
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Figure 5 Tumorigenicity of PANC-1 cell lines stably transfected with the
expression plasmids of hyperstable U1snRNAs. PANC-1 (A), Pr1A-4 (B),
Pr1A-2 (C), Pr1S (D), Pr3A-5 (E), and Pr3S (F). Cells (3610
6) were in-
jected subcutaneously into 6 week-old male BALB/c nu/nu mice. The ani-
mals were monitored for tumour formation over 3 months and
photographed. No tumour developed with Pr1A-4 (B) and Pr3A-5 (E).
Arrows in (C) indicate a tumour contour. (G) Tumour volume in nude
mice was calculated as described (Gray et al, 1993) at 3 months following
subcutaneous injection.
Table 1 Summary of biological properties of the stable hyperstable U1snRNA transfectants
Cell K-ras p21
a Morphological heterogeneity Growth rate Hyperstable U1snRNA
b Tumorigenicity
b
PANC-1 pl ? 7 ? 7 ++
Pr1A 1 ; 7 ? + n.d.
2 ; 7 ? 7 +
3 ; 7 ? + n.d.
4 ; ++ ; + 7
5 ; 7 ? 7 n.d.
6 ; ++47
c ;4?
c 7 n.d.
Pr1S Pl ? 7 ? ++ +
Pr3A 1 ? 7 ? 7 n.d.
2 ? 7 ? + n.d.
3 ? ++47
c ;4?
c 7 n.d.
4 ; +++ ; + 7
5 ; ++ ; + 7
Pr3S pl ? 7 ? ++ +
Pwt pl ? 7 ? 7 ++
The clone numbers of Pr1A and Pr3A were indicated. Also pl indicated these cell lines were obtained as pooled G418 resistant colonies. n.d.
means not determined.
aThe K-ras p21 expression was examined at early passages as Figure 5A.
bThese results were obtained after the expan-
sion of cell lines for in vivo injection.
cThese clones rapidly lost morphological heterogeneity as increase in growth rate.
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A novel plasmid expressing antisense RNA based on the
U1snRNA gene has been constructed. The antisense sequence
was expressed as hyperstable U1snRNA that exhibited a uniquely
high stability of binding with the target RNA. This vector system
was able to acquire stably 60 base-long antisense RNA. We tested
the efﬁcacy of the vector system by inserting antisense sequences
against the human K-ras gene, and found that two of these
hyperstable U1snRNAs could induce cell death when transduced
into pancreatic cancer cell lines harbouring the activated K-ras
oncogene. Furthermore, intraperitoneal administration of these
expression plasmids was found to suppress the peritoneal disse-
mination of implanted pancreatic cancer cells. Although a loss
of antisense-transfected cells during clonal expansion has been
described, for example, in oesophageal cancer cells with antisense
to cyclin D1 (Zhou et al, 1995), no such phenomenon has ever
been reported using antisense oligomers or antisense expression
vectors against the K-ras gene (Mukhopadhyay et al, 1991; Zhang
et al, 1993; Aoki et al, 1995, 1997; Alemany et al, 1996; Kita et
al, 1999). The induction of cell death was noticed primarily as a
reduction in the number of viable cells following transient trans-
fection of r1A or r3A. This observation was supported by careful
cell counting and ﬂow cytometer analysis (data not shown).
Further evidence was provided by analysis using the Pr1A and
Pr3A clones, obtained as stable r1A and r3A transfectants.
Although any comparison between isolated cell clones and
pooled cells needs careful interpretation, the colonies of these
stable transfectants displayed obvious characteristics, such as a
slow growth rate and morphological heterogeneity, which were
not observed in the colonies of any control transfectants. The
presence of numerous multinucleated giant cells indicated
strongly that the hyperstable U1snRNA exerted its effect on the
cell cycle, possibly in the mitotic phase rather than S phase,
because of the multiple nuclei suggesting that these cells had
passed through several rounds of DNA replication. These trans-
fectants also produced a signiﬁcant number of ﬂoating cells,
which suggested that a fraction of the transfectants continuously
died. Cumulatively, these results provide strong evidence that the
hyperstable U1snRNA from r1A and r3A were able to arrest cell
proliferation and induce cell death in pancreatic cancer cell lines
harbouring the activated K-ras gene.
The induction of cell death so soon after gene transduction
hampered biochemical analysis of the underlying mechanism.
However, the analysis of stable transfectants provided several
clues that suggested that r1A and r3A interfered with the
production of K-ras p21. First of all, in the Pr1A and Pr3A
clones, there was a correlation between the expression of hyper-
stable U1snRNA, the reduction of K-ras p21, the morphological
heterogeneity, and the loss of tumorigenicity. Furthermore, rever-
sion of cell morphology during cell culture was associated with
an elevation in K-ras p21 levels and a decline in the expression
of the hyperstable U1snRNA. In addition, the insensitivity of
BxPC-3 to these hyperstable U1snRNAs was also consistent with
the antisense effect against K-ras, since BxPC-3 was not affected
by any antisense strategies in previous studies (Aoki et al, 1995,
1997; Kita et al, 1999).
The reason for the reduction in K-ras production interfering
with cell survival is unknown. However, studies using knockout
mice demonstrated that the K-ras gene is essential for certain cell
lineages during embryogenesis (Johnson et al, 1997; Koera et al,
1997). If the survival of pancreatic cancer cells depends to any
extent on the expression of an activated K-ras gene, then a reduc-
tion in gene expression to less than a certain critical level might be
lethal to these cells.
Using hyperstable U1snRNA, one concern is non-speciﬁc
toxicity arising from the use of a general splicing factor as a
carrier of an antisense sequence. Theoretically, hyperstable
U1snRNA does have a higher binding stability, but only for
its target 5'ss, and not for non-homologous 5'ss regions.
Although there is an essential difference with respect to hyper-
stable U1snRNA, mutated U1snRNAs in the 5'-free end
sequence could be expressed stably in culture cells (Cohen et
al, 1993) and in transgenic ﬂies (Lo et al, 1994), suggesting that
the cells can tolerate the expression of mutated U1snRNA to a
certain extent.
In this study, non-speciﬁc toxicity of hyperstable U1snRNA
was not observed, since all hyperstable U1snRNAs, except r1A
and r3A, did not exert any inhibitory effect on pancreatic
cancer cell lines. Even r1A and r3A did not affect cell growth
of BxPC-3 and COS-1. Furthermore, in vivo injection of a
DNA/liposome complex did not produce any recognisable tissue
damage in the host animals, while it prevented the peritoneal
dissemination of inoculated pancreatic cancer cells. Aoki et al
(1995) studied the systemic distribution of DNA conjugated
with liposome and reported that it could be found in all organs
except the brain. Therefore, we considered that these hyperstable
U1snRNAs are no more toxic than conventional antisense RNA
against the K-ras gene, and might be useful for therapeutic
purposes.
We were also surprised by the ﬁnding that a shift of merely 20
bases in the target sequences, which still overlapped 40 bases with
each other, could abolish the effect of the hyperstable U1snRNA,
although it has been known that a slight shift of the target site
can affect the inhibitory potency of antisense oligonucleotides. This
raises the possibility that the binding of these hyperstable
U1snRNAs to the target site may be strictly regulated, in such a
way that the 20 base-shift rendered them unable to bind with
the target RNA. Alternatively, even though hyperstable U1snRNAs
could bind to their target sequences, the outcome of whether they
disturb or permit normal processing of the target pre-mRNA may
depend on their relative binding sites to the 5'ss. Indeed, the target
sites of r1A and r3A were in the 5' exon side of 5'ss regions.
Further study is necessary to determine whether the effect of
hyperstable U1snRNA actually depends on its position relative to
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Table 2 Tumours in the peritoneal cavity of the mice administered with
the hyperstable U1snRNA expression vector conjugated with liposome
Tumour formation
Administered samples Mouse no. Mesenterium Pancreas Liver
r1A 1 77 7
2 77 7
3+ 77
r1S 1 +++ 7 +
2 +++ ++ +
3 +++ +++ +
r3A 1 77 7
2 77 7
3 77 7
r3S 1 +++ ++ +
2 ++ +++ 7
3 ++ +++ +
Liposome alone 1 +++ ++ 7
2+ + + 7
3+ + 7 +
TE 1 + ++ +
2+ + + +
3 +++ ++ 7
Tumours on the mesenterium and pancreas were evaluated on the basis of the maxi-
mum size and number as follows: +, 53 mm in size and 53 in number; ++, 3–
6 mm in size or 3–6 in number; +++, 46 mm in size or 46 in number.
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anticipated before.
Our results demonstrate that the hyperstable U1snRNA is much
more effective than conventional antisense RNA against K-ras,
despite the fact that we used relatively short antisense sequences
as an in vivo antisense expression vector. By directing the antisense
RNA to the 5'ss region of pre-mRNA in the form of hyperstable
U1snRNA, this vector system gives us the potential to select the
target sequence systematically in the vicinity of a 5'ss in any gene.
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